Deep Vein Thrombosis and Pulmonary Embolism in the Apixaban Era: From Bench to Bedside

Author(s): Pavel Poredos*, Mateja Kaja Jezovnik

Journal Name: Current Drug Targets

Volume 19 , Issue 6 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: The traditional treatment of venous thromboembolism (VTE) with heparin and warfarin has numerous limitations. New oral anticoagulants represent the promising alternative with the potential to overcome the limitations of traditional treatment.

Objective: Apixaban is an oral factor Xa inhibitor with a rapid onset of action and predictable pharmacokinetics that allows a fixed dose regimen. With this characteristic apixaban overcomes many limitations and simplifies treatment of VTE eliminating the need for initial parenteral anticoagulant therapy and laboratory monitoring.

Results: Fixed-dose regimen of oral apixaban alone is as effective as conventional treatment regimen and is associated with a clinically relevant reduction of major bleeding. Extended anticoagulation with apixaban with either a treatment dose (5 mg twice daily) or thromboprophylactic dose (2.5 mg twice daily) reduces the risk of recurrent venous thromboembolism without increase in the rate of major bleeding.

Conclusion: Therefore, apixaban provides a simple, effective and safe alternative to conventional acute or long-term treatment of VTE.

Keywords: Bleeding complications, management, new oral anticoagulants, venous thrombosis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 16 April, 2018
Page: [577 - 580]
Pages: 4
DOI: 10.2174/1389450116666150518100106
Price: $65

Article Metrics

PDF: 28
PRC: 1